VISCHER advises Inthera Bioscience, a Zurich based biopharmaceutical company focused on the development of first-in-class targeted small molecule therapies for solid tumors.

Inthera has discovered potent disruptors of hypoxia-inducible signaling for the treatment of solid tumors and targeted agents against HPV-associated cancer, which are in pre-clinical development.

The VISCHER team includes Christian Wyss, Matthias Staehelin and Dania Salvisberg-Schneider (all Corporate)